High Potential Stock Alert Today 📈

📈 Join us for LIVE TRADING action all day long in the 📈

 Market Master’s trading room

Good Morning! Jeff here.

What a great game last night!  I am big fans of both the Celtics and the Mavs, but it is pretty clear that Boston has the best team right now.

I’ve lived in the New England area for the last 15 years, and I have to say you get spoiled with great sports teams when you call this place home.  They are so lucky! 

Do you know who else has been lucky lately?

Anyone who isn’t betting against the market!

Just when you thought things were a little too overextended to the upside, the market always has a way of proving the skeptics wrong.

I am so glad I have been following the price action, and not listening to my stupid opinions lately.  It has helped me make a lot of money lately!

Today, I want to show you a new stock idea I have never discussed before.

I think it presents a very compelling opportunity right now, and you need to look at it quickly.

Go to your platform and pull up Silo Pharma (SILO) right now, and let’s take a look.

What I see right now fits perfectly with what I call a “bottom bouncer” play.

While stocks can always theoretically go to $0, there usually comes a time when a stock gets so oversold in the short-term that it is due for a bounce higher.

When you can time those bounces right, it can really work out well because the upside move can be very fast, while the downside is likely to be limited if you use a proper stop loss.

Look at the chart right now and let me show you what I mean…

As you can see, SILO has had a rough couple of weeks leading up today.

Most of this was self-inflicted as the company just announced a finanicing deal that drove the stock price lower (you can read it here).

Here’s what makes it so interesting though.  The financing deal was over $2 a share, and look at where the stock is now… just hovering over $1.

I’m not going to try and claim exactly what price the stock should be right now, but I think this move lower has been an overreaction from the market.

When it starts to move up again, I think it could result in a very nice bounce opportunity, at least for a quick score.

We already saw one bounce attempt this week, and it quickly took SILO to $1.50.  

Just a small move like that would be well over a 30% spike from today’s price.

On the downside, we have seen $1.08 as a support line for the last week.  If I saw the stock close below that level, I would say this is not working out and move to the sidelines.

Overall, I think SILO is a great opportunity to look at right now.

If it starts to reverse course and move higher, I think it could be very quick, so you’ll need to be prepared.

Things could get spicy today! 🌶️

As you are doing your research, Silo Pharma Inc. (SILO) is a developmental-stage biopharma company developing novel treatments for conditions such as PTSD, stress-induced psychiatric disorders, chronic pain conditions, and fibromyalgia.

The company is especially focused on psychedelic-based compounds and has partnered with leading institutions such as Columbia University and University of Maryland, Baltimore.

By partnering with these institutions, the company hopes to use the FDA’s streamlined and lower-cost 505(b)(2) pathway for drug approval, which allows the inclusion of external safety and efficacy data in Investigational New Drug (IND) applications.

All the therapeutics in SILO’s pipeline are in a preclinical phase, but its leading candidate is SPC-15, which targets stress-induced affective disorders such as anxiety and PTSD.

SPC-15 is being developed under a 2021 sponsored research agreement with Columbia University, which gave SILO the option to exclusively license SPC-15 for further development, manufacture, and commercialization.

SILO expects to exercise that option “in the first half of 2024” — so later this month, presumably.

SPC-15 is an intranasal prophylactic treatment for PTSD that the company intends for military personnel, first responders, and others at high risk of the condition.

Just last week, SILO announced its submission of a pre-Investigational New Drug (pre-IND) briefing package and meeting request to the FDA for SPC-15, noting its positive results from a small animal dose-ranging study completed in February.

SILO’s next prioritized program is SP-26, which is an injectable, time-release ketamine-loaded implant for treatment of chronic pain, especially pain related to fibromyalgia.

According to the company, SP-26 “holds the potential to be the first at-home ketamine treatment approved for chronic pain management.”

Last Friday, SILO revealed positive production news about the implant.

CEO Eric Weisblum said, “The results so far in our ongoing SP-26 pre-clinical research bring us closer to determining the optimal formulation for future pre-clinical testing models.”

A third program is SP-14, which is a novel therapeutic also developed by Columbia University that targets Alzheimer’s. 

Preclinical testing and proof-of-concept is being led by investor Dr. Christine Denny of Columbia.

This intranasal, ketamine-related therapeutic has been found to reduce anxiety in animal studies.

In April, SILO announced that it had exercised its option to license SP-14 from Columbia.

Lastly, in partnership with the University of Maryland, Baltimore, SILO is developing SPU-16, a patented peptide that targets the central nervous system for potential treatment of multiple sclerosis.

Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: With the market trading at nose-bleed levels right now, I think it is a great time to look at some of the few oversold opportunities that are out there currently.  I think SILO is a great idea to consider right now, for the reasons I discussed above. 

When SILO moves, it will be very fast… so have a plan in place!

To Your Success,

P.S. Make sure you join me and over 1000 traders in the Market Master’s trading room today for live trading signals and education. You can access it at no cost right now. 

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull

*Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Sica Media for advertising Silo Pharma, Inc for a one day marketing program on June 13, 2024. This amount was paid by someone else not connected to Silo Pharma, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into Silo Pharma, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.